Ass. Prof. Fotios Loupakis, Prof. Hans Prenen and Ass. Prof. Joleen Hubbard discuss the Clinical Question: How to treat (or not) elderly colorectal cancer patients? Unfit: a relative concept

Hans Prenen obtained his medical degree and PhD at the Catholic University Leuven. He is currently the head of the Medical Oncology Department at the University Hospital Antwerp and director of the Oncology Clinical Trial Unit. He is member of several scientific organisations including the Belgian Society of Medical Oncology (board member since 2015) and the European Society of Medical oncology (scientific committee). He is a recognised international expert in the field of cancer and is regularly invited to national and international meetings and has published more than 160 peer reviewed scientific papers. He is principal investigator of several clinical trials with a focus on phase 1 and basket trials. His research interests relate to translational studies on targeted therapies, new anticancer therapies and understanding the molecular changes induced by anticancer therapy.

Dr Joleen Hubbard is Deputy Director of Clinical Research and Academic Affairs for the Allina Health Cancer Institute in Minneapolis, Minnesota.  She was previously Assistant Professor of Medical Oncology at Mayo Clinic. She completed medical school and residency at the University of Minnesota and haematology/oncology training at Mayo Clinic, Rochester, Minnesota. Dr Hubbard specialises in the treatment of gastrointestinal cancers, focusing on colorectal cancer. Dr Hubbard is the PI of several phase I clinical trials, investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology with a special interest in clinical and biologic markers of frailty. She serves as a member of the Cancer in the Elderly, as well as the Health Reported Outcomes and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network. 

Assoc. Prof. Joleen Hubbard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Advisory boards: Bayer, Merck, BeiGene, Incyte

Research funding to institution: Merck, Boston Biomedical, Treos Bio, Senhwa Pharmaceuticals, Bayer, Incyte, TriOncology, Seattle Genetics, Hutchison MediPharma, Pionyr Immunotherapeutics, Trovogene, G1 Therapeutics, Roche

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from Bayer and BeiGene Europe.

Meet the experts

Other programmes of interest

Conference update
Oncology 
Oncogene-addicted NSCLC: Highlights from ASCO 2024

The latest non-small cell lung cancer data presented at ASCO

Experts
Prof. Nicolas Girard
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Upper lower GI cancer update ASCO 2024 Conference update
Oncology 
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock 76 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
Conference update

Episode

1

of 4

episode
Oncology 
ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO

Experts
Prof. Mark Socinski
  • clock 4 MIN
  • calendar Jun 2024

Conference update

Episode

2

of 4

episode
Oncology 
ASCO 2024 breast cancer highlights

How could the data impact clinical practice?

Experts
Prof. Shaheenah Dawood
  • clock 3 MIN
  • calendar Jun 2024

Conference update

Episode

3

of 4

episode
Oncology 
ASCO 2024 HCC highlights

How could the latest clinical trial data impact the management of hepatocellular carcinoma?

Experts
Prof. Dr Peter R. Galle
  • clock 1 MIN
  • calendar Jun 2024